The pathway to commercialization for nanomedicine

被引：31

作者：

Flynn, Ted ^{[1
]}

Wei, Chiming ^{[2
]}

机构：

[1] Potomac Investment Capital LLC, Sterling, VA USA

[2] Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA

来源：

NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE | 2005年 / 1卷 / 01期

关键词：

Nanomedicine; Nanotechnology; Commercialization; Business; Development;

D O I：

10.1016/j.nano.2004.11.010

中图分类号：

TB3 [工程材料学];

学科分类号：

0805 ; 080502 ;

摘要：

Nanomedicine is a global opportunity that will change the face of medicine and drug delivery in the next 20 years. To date, US firms have focused primarily on the science and less on the commercial application of nanomedicine. As a result, there remain significant obstacles in bringing a nanomedicine product to market. Overcoming those obstacles will require a multidisciplinary approach to commercialization. This article will look at the emerging nanomedicine market, the current view from the investment community, and some of the obstacles facing the commercialization of nanomedicine science. (C) 2005 Published by Elsevier Inc.

引用

页码：47 / 51

页数：5